New carbamoylpiperidines as human platelet aggregation inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Platelet aggregation is crucial in thrombosis and hemostasis.
• Adenosine diphosphate (ADP) and collagen are key agonists in platelet activation.
• Nitric oxide (NO) is a known regulator of platelet function.

Purpose of the Study:

• To design, synthesize, and evaluate novel 3-carbamoylpiperidines (nipecotamides) as inhibitors of ADP-induced platelet aggregation.
• To investigate the structure-activity relationships (SAR) of nipecotamides, particularly focusing on the role of nitric ester moieties.
• To elucidate the mechanism of action of potent nipecotamide derivatives on platelet signaling pathways.

Main Methods:

• Synthesis of a series of nipecotamide derivatives.
• In vitro testing of anti-platelet aggregation activity against ADP-induced human platelet aggregation.
• Structure-activity relationship analysis, including stereoselectivity studies.
• Measurement of intracellular signaling molecules like inositol trisphosphate (IP3) and assessment of phosphoinositide turnover.

Main Results:

• Nipecotamides with a nitric ester moiety demonstrated significantly enhanced inhibitory activity against platelet aggregation compared to analogs lacking this group.
• Stereoselectivity was observed, with the meso isomer showing approximately twice the potency of the diastereomeric mixture.
• The most active compounds inhibited basal and collagen-induced increases in platelet IP3 levels and phosphoinositide turnover.
• Replacement of the nitric ester with hydroxyl, ester, or alkyl groups markedly reduced inhibitory potential.

Conclusions:

• Incorporation of a nitric ester moiety into the nipecotamide scaffold is a promising strategy for developing potent anti-platelet agents.
• The stereochemistry of the nipecotamide derivatives plays a critical role in their aggregation-inhibitory efficacy.
• Nipecotamides act by interfering with key platelet activation pathways, including IP3 signaling and phosphoinositide turnover.